MONMOUTH JUNCTION, N.J.,
Sept. 18, 2014 /PRNewswire/
-- CytoSorbents Corporation (OTCQB: CTSO), a critical care
immunotherapy company using its CytoSorb® blood purification
technology to treat life-threatening inflammatory conditions such
as sepsis, is a proud sponsor of:
- World Sepsis Day 2014 organized by the Global Sepsis
Alliance
- The short film "97 seconds for sepsis" produced by the Global
Sepsis Alliance
- The 3rd Annual Celebration of Sepsis Heroes event
hosted by the Sepsis Alliance tonight in New York City at Arena NYC (135 West 41st Street) from
7:00-10:00 PM EDT with a keynote
address by Mr. Paul Levy, former
President and CEO of Beth Israel Deaconess Medical Center in
Boston
- The Roger Bone Award, awarded by the German Sepsis Society to
recognize an outstanding publication in clinical sepsis research
for young scientists in German-speaking countries. Dr. Bone
was a pioneer in understanding the connection
between uncontrolled inflammation and organ failure in sepsis
pathology and one of the fathers of critical care
immunotherapy
- Sepsis awareness and education at the University Medical Center
Hamburg-Eppendorf
In addition, CytoSorbents' partners have also been active.
- Biocon Ltd, CytoSorbents' strategic partner in India, is also a sponsor of World Sepsis
Day. Biocon recently completed a five city tour in
India, including the Delhi Society
of Critical Care Medicine Conference, with Dr. med. Axel Nierhaus from University Medical Center
Hamburg-Eppendorf, Germany. The tour brought together more
than 350 leading intensivists from across the country to learn more
about CytoSorb® and its application in sepsis and other
life-threatening illnesses
- WMC Medical, the distributor of CytoSorb® in the Netherlands, also sponsored the
1st Netherlands International Sepsis Symposium that took
place last week.
Sepsis is a medical emergency that results from of an
overzealous immune response to a serious infection, driven by a
"cytokine storm," leading to widespread deadly inflammation that
can cause multiple organ failure, immune paralysis, and
death. According to the Global Sepsis Alliance, sepsis
afflicts 20-30 million people each year worldwide, and kills
someone every few seconds, despite the use of antibiotics.
Dr. Phillip Chan, MD, PhD, CEO of
CytoSorbents stated, "The impact of sepsis to human life is
staggering and the problem continues to worsen. We hope to change
this trend with our CytoSorb® therapy. While antibiotics work
to control the infection, CytoSorb® works to control the excessive
inflammatory response through cytokine reduction, removal of
bacterial toxins, and redirection of activated white blood cells to
the area of infection and away from healthy organs. In doing
so, the goal is to prevent or treat organ failure, the leading
cause of death in sepsis. We are pleased to support the
efforts of these organizations in the fight against this common
foe."
About the Global Sepsis Alliance
The Global Sepsis Alliance (GSA) is a non-profit organization
supporting the efforts of over 1 million caregivers in more than 70
countries as they seek to better understand and combat what many
experts believe to be the leading cause of death worldwide: sepsis.
The GSA has rallied the Global Sepsis Community to elevate public,
philanthropic and governmental awareness, understanding and support
of sepsis and to accelerate collaboration among researchers,
clinicians, associated working groups and those dedicated to
supporting them.
About the German Sepsis Society
The German Sepsis Society (GSS) is the primary medical society
in Germany whose mission is to
educate and increase public and professional awareness about
sepsis. The organization brings together leaders in sepsis
research, diagnostics, treatment, and education in order to also
encourage new research, recognize valuable scientific
contributions, and foster collaborations to help save lives.
A major goal is to support the rapid implementation of effective
sepsis diagnostics and therapies into the standard of care
treatment for sepsis. Members of the GSS have been heavily
involved with SepNet, or the Sepsis Competence Network, a
consortium of hospitals and investigators funded for 10 years by
the German Federal Ministry of Education to conduct research and
clinical trials in sepsis. The GSS also initiated the
foundation of the organization, German Sepsis Aid, by people who
survived sepsis and their relatives, to provide assistance,
information, and networking for those whose lives have been touched
by sepsis. For more information, visit
www.sepsis-gesellschaft.de/DSG/Englisch
About the Sepsis Alliance™ and Sepsis Heroes Evening
The Sepsis Alliance is a charitable organization run by a team
of dedicated laypeople and professionals who share a strong
commitment to battling sepsis. The goal is to raise awareness
of sepsis through information and educational material so it can be
detected and treated early enough that no harm is done. The
Sepsis Heroes Evening is an award reception, being held in
New York City, designed to raise
awareness of sepsis and to recognize the unique contributions of
individuals who have committed their time and energy for the
cause. This year, Sepsis Alliance honors two organizations,
Every Mother Counts and Intermountain Healthcare, and three
individuals, Jeff and Helene Zehnder
and Laura Messineo, for their
contributions to increasing sepsis awareness and improving
treatment response. For more information, visit
www.sepsisalliance.org
About World Sepsis Day
World Sepsis Day is an initiative of the Global Sepsis Alliance
(GSA) and its founding non-profit members: The World
Federation of Societies of Intensive and Critical Care Medicine,
the World Federation of Pediatric Intensive and Critical Care
Societies, the World Federation of Critical Care Nurses, the
International Sepsis Forum, and the Sepsis Alliance. The
goals of World Sepsis Day are to:
- Reduce the incidence of sepsis through effective prevention
strategies
- Increase sepsis survival rates for all population groups around
the world
- Provide better access to suitable rehabilitation services for
people everywhere
- Increase awareness and understanding of sepsis among healthcare
professionals and the general public
For more information, visit www.world-sepsis-day.org
About CytoSorbents Corporation
CytoSorbents Corporation is a critical care focused
immunotherapy company using blood purification to control severe
inflammation -- with the goal of preventing or treating multiple
organ failure in life-threatening illnesses. Organ failure is the
cause of nearly half of all deaths in the intensive care unit, with
little to improve clinical outcome. CytoSorb®, the Company's
flagship product, is approved in the European Union as a safe and
effective extracorporeal cytokine adsorber, designed to reduce the
"cytokine storm" that could otherwise cause massive inflammation,
organ failure and death in common critical illnesses such as
sepsis, burn injury, trauma, lung injury, and pancreatitis. These
are conditions where the risk of death is extremely high, yet no
effective treatments exist. CytoSorbents' purification technologies
are based on biocompatible, highly porous polymer beads that can
actively remove toxic substances from blood and other bodily fluids
by pore capture and surface adsorption. CytoSorbents has numerous
products under development based upon this unique blood
purification technology, protected by 32 issued US patents and
multiple applications pending, including HemoDefend™, ContrastSorb,
DrugSorb, and others. Additional information is available for
download on the Company's
website: http://www.cytosorbents.com
Forward-Looking Statements
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements in this press release are not promises or guarantees and
are subject to risks and uncertainties that could cause our actual
results to differ materially from those anticipated. These
statements are based on management's current expectations and
assumptions and are naturally subject to uncertainty and changes in
circumstances. We caution you not to place undue reliance upon any
such forward-looking statements. Actual results may differ
materially from those expressed or implied by the statements
herein. Risk factors are detailed in the Company's Form 10-K filed
with the SEC on March 31, 2014, which
is available at http://www.sec.gov.
Logo -
http://photos.prnewswire.com/prnh/20140408/MM00899LOGO
SOURCE CytoSorbents Corporation